medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2026-7-37-43medalphabet-5068Research ArticleСтатьиРеферентные интервалы для специфических параметров гемостаза, определяемых на автоматическом коагулометреReference values for specific parameters of hemostasis determined with the automated analyzerhttps://orcid.org/0000-0001-5235-2356ГоргидзеЛ. А.GorgidzeL. A.

Горгидзе Лана Анзоровна, к. б. н., биолог в экспресс‑лаборатории отдела реанимации и интенсивной терапии с дневным стационаром и группой гемодиализа

Москва

Gorgidze Lana A., PhD Bio Sci, biologist at express laboratory of Intensive Care Dept with a Day Hospital and a Hemodialysis Group

Moscow

lana380@mail.ruhttps://orcid.org/0000-0003-1492-1735МамлееваС. Ю.MamleevaS. Yu.

Мамлеева Светлана Юрьевна, врач клинико‑лабораторной диагностики, зав. экспресс‑лабораторией отдела реанимации и интенсивной терапии с дневным стационаром и группой гемодиализа

Москва

Mamleeva Svetlana Yu., clinical laboratory diagnostics specialist, head of Express Laboratory of Intensive Care Dept with a Day Hospital and a Hemodialysis Group

Moscow

https://orcid.org/0000-0002-1118-6969КамельскихД. В.KamelskikhD. V.

Камельских Денис Владимирович, врач‑трансфузиолог, зав. отделением организации и обеспечения безопасности трансфузиологии

Москва

Kamelskikh Denis V., transfusion specialist, head of Transfusiology Organization and Safety Dept

Moscow

kamelskikh.d@blood.ruhttps://orcid.org/0000-0001-8818-8949ГалстянГ. М.GalstyanG. M.

Галстян Геннадий Мартинович, д. м. н., зав. отделом реанимации и интенсивной терапии

Москва

Galstyan Gennady M., Dr Med Sci (habil.), head of Dept of Resuscitation and Intensive Care

Moscow

gengalst@gmail.comФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава РоссииРоссияNational Medical Research Center for HematologyRussian Federation20260306202607Современная лаборатория (1)3743Copyright © Горгидзе Л.А., Мамлеева С.Ю., Камельских Д.В., Галстян Г.М., 20262026Горгидзе Л.А., Мамлеева С.Ю., Камельских Д.В., Галстян Г.М.Gorgidze L.A., Mamleeva S.Y., Kamelskikh D.V., Galstyan G.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/5068Введение

Введение. Важное значение для клинической практики имеют референтные интервалы активности фактора Виллебранда, ристоцетин‑ кофакторной активности фактора Виллебранда, антигена фактора Виллебранда, активности фактора свертывания VIII, определяемой хромогенным методом, Д‑димера и активности ингибитора активатора плазминогена урокиназного типа. Однако эти референтные интервалы варьируют в зависимости от типа аналитической системы и используемых для диагностики реагентов.

Цель исследования

Цель исследования. Определить референтные интервалы параметров системы гемостаза.

Материалы и методы

Материалы и методы. После получения информированного добровольного согласия донора на медицинское обследование и донацию крови и (или) ее компонентов, образцы крови были получены от 100 доноров крови и (или) ее компонентов обоих полов: 51 мужчины (51%) и 49 женщин (49%). Использовали анализатор гемостаза Sysmex CS‑2000i (Sysmex Corporation, Япония) и реагенты компании Siemens» (Healthcare GmbH, Германия).

Результаты

Результаты. Полученные референтные интервалы для активности фактора Виллебранда (46,65–181,45 %), ристоцетин‑кофакторной активности фактора Виллебранда (16,77–164,37 %), антигена фактора Виллебранда (52,11–169,27 %), активности FVIII, определяемой хромогенным методом (45,08–158,35%), Д‑димера (17,69–368,13 мкг/л) и активности ингибитора активатора плазминогена урокиназного типа (–2,54–4,48 Ед/мл) были сопоставлены с данными литературы и данными, представленными в инструкциях к используемым реагентам. Полученные результаты для антигена фактора Виллебранда (48,11–174,12 %) и Д‑димера (17,69–368,13 мкг/л) сопоставимы с имеющимися в литературе данными, данных по другим исследуемым параметрам гемостаза для анализатора Sysmex CS‑2000i и используемых в работе реагентов нет. Полученные референтные интервалы согласуются с рекомендациями компании‑ производителя.

Заключение

Заключение. Референтные значения могут различаться в зависимости от используемых аналитических систем и наборов реагентов, что подтверждает необходимость локального выведения или валидацию референтных интервалов для каждой конкретной лаборатории.

The article defines reference values for von Willebrand factor activity, von Willebrand factor ristocetin cofactor activity, von Willebrand factor antigen, Factor VIII Chromogenic assay activity, d‑dimer and Plasminogen activator inhibitor activity according to existing standards on the automatic coagulometer Sysmex CS‑2000i.

The aim of the study

The aim of the study: to determine reference values for specific parameters of the hemostasis, which may vary depending on the type of analyzer and utilized reagents.

Materials and methods

Materials and methods. After receiving informed voluntary consent from donors for medical survey and blood and (or) its components donation, blood samples were obtained from 100 donors of blood and (or) its components of both sexes: 51 males (51%) и 49 females (49%). We established reference values with the Sysmex CS‑2000i (Sysmex Corporation, Japan) hemostasis analyzer and reagents from Siemens (Healthcare GmbH, Germany).

Results

Results. Reference values obtained for von Willebrand factor activity (46,65–181,45%), von Willebrand factor ristocetin cofactor activity (16,77– 164,37%), von Willebrand factor antigen (52,11% – 169,27%), Factor VIII chromogenic assay (45,08–158,35%), d‑dimer (17,69–368,13 mcg/l) and Plasminogen activator inhibitor activity (–2,54–4,48 E/ml), were compared with the literature data and the data presented in the instructions for the reagents used. The results obtained for von Willebrand factor antigen (52,11–169,27%) and d‑dimer (17,69–368,13 mcg/l) are comparable to the available data. There are no data on other studied parameters of hemostasis for the Sysmex CS‑2000i analyzer and the reagents used in the work. The obtained reference intervals are generally consistent with the manufacturer’s recommendations.

Conclusions

Conclusions. Reference values vary significantly depending on the analytical systems and reagent kits used, which confirms the need for local derivation or validation of reference intervals for each specific analytical system and in each laboratory.

референтные интервалыспецифические параметры гемостазакоагулометр Sysmex CS‑2000ireference intervalshemostasis parametersSysmex CS‑2000i analyzerАвторы статьи выражают огромную благодарность Зозуле Надежде Ивановне – доктору медицинских наук, врачу гематологу, заведующей Клинико диагностическим отделением гематологии и нарушений гемостаза, ФГБУ «Национальный медицинский исследовательский центр гематологии» и Яковлевой Елене Владимировне – кандидату медицинских наук, врачу гематологу Клинико диагностического отделения гематологии и нарушений гемостаза, ФГБУ «Национальный медицинский исследовательский центр гематологии» за ценные советы и замечания при написании данной статьи.ReferencesLillicrap D. Von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013; 122 (23): 3735–3740. DOI: 10.1182/blood-2013-06-498303Lillicrap D. Von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood. 2013; 122 (23): 3735–3740. DOI: 10.1182/blood-2013-06-498303Лихачева Е. А., Полянская Т. Ю., Зоренко В. Ю. Международный опыт диагностики и лечения болезни виллебранда. Гематология и трансфузиология. 2013; 58 (4): 45–9.Likhacheva E.A., Polyanskaya T. Yu., Zorenko V. Yu. International experience in the diagnosis and treatment of von Willebrand disease. Hematology and Transfusiology. 2013; 58 (4): 45–9. (In Russ.).Lippi G., Favaloro E.J., Franchini M. Dangers in the practice of defensive medicine in hemostasis testing for investigation of bleeding or thrombosis: part I – routine coagulation testing. Review Semin Thromb Hemost. 2014; 40 (7): 812–24. DOI: 10.1055/s-0034-1394108Lippi G., Favaloro E.J., Franchini M. Dangers in the practice of defensive medicine in hemostasis testing for investigation of bleeding or thrombosis: part I – routine coagulation testing. Review Semin Thromb Hemost. 2014; 40 (7): 812–24. DOI: 10.1055/s-0034-1394108Yildiz S.Y., Kuru P., Oner E.T., Agirbasil M. Functional Stability of Plasminogen Activator Inhibitor 1. The Scientific World Journal. 2014; 11 pages. DOI: 10.1155/2014/858293Yildiz S.Y., Kuru P., Oner E.T., Agirbasil M. Functional Stability of Plasminogen Activator Inhibitor 1. The Scientific World Journal. 2014; 11 pages. DOI: 10.1155/2014/858293Андреева Т.А., Жарков П.А., Зозуля Н.И., Зоренко В.Ю., Константинова В.Н., Лебедев В.В., Мамаев А.Н., Маркова И.В., Петров В.Ю., Полянская Т.Ю., Шиллер Е.Э. Методические рекомендации по ведению больных Гемофилией А, получающих эмицизумаб. Гематология и трансфузиология. 2022; 67 (2): 267–280. DOI: 10.35754/0234-5730-2022-67-2-267-280Andreeva T. A., Zharkov P. A., Zozulya N. I., Zorenko V. Yu., Konstantinova V. N., Lebedev V.V., Mamaev A.N., Markova I.V., Petrov V. Yu., Polyanskaya T. Yu., Schiller E.E. Management of patients with hemophilia a on emicizumab prophylactic treatment: recommendation from russian experts. Hematology and transfusiology. 2022; 67 (2): 267–280. (In Russ.). DOI: 10.35754/0234-5730-2022-67-2-267-280Yee A., Kretz C.A. Von Willebrand factor: Form for function. Semin Thromb Hemost. 2014; 40 (1): 17–27. DOI: 10.1055/s-0033-1363155Yee A., Kretz C.A. Von Willebrand factor: Form for function. Semin Thromb Hemost. 2014; 40 (1): 17–27. DOI: 10.1055/s-0033-1363155Клинические рекомендации по диагностике и лечению болезни Виллебранда. Утверждены на IV Конгрессе гематологов России; 2018 г.Clinical guidelines for the diagnosis and treatment of Willebrand’s disease. Approved at the IV Congress of Hematologists of Russia; 2018. (In Russ.).Lethagen S. von Willebrand’s disease: pathogenesis and clinical aspects. Crit Rev Oncol Hematol. 1993; 15: 1–11.Lethagen S. von Willebrand’s disease: pathogenesis and clinical aspects. Crit Rev Oncol Hematol. 1993; 15: 1–11.Goodeve A.C. The genetic bases of von Willebrand disease. Blood Rev. 2010; 24 (3): 123–34. DOI: 10.1016/j.blre.2010.03.003Goodeve A.C. The genetic bases of von Willebrand disease. Blood Rev. 2010; 24 (3): 123–34. DOI: 10.1016/j.blre.2010.03.003Bharati K.P., Prashanth U.R Von Willebrand disease: an overview. Indian J Pharm Sci. 2011; 73 (1): 7–16. DOI: 10.4103/0250-474X.89751Bharati K.P., Prashanth U.R Von Willebrand disease: an overview. Indian J Pharm Sci. 2011; 73 (1): 7–16. DOI: 10.4103/0250-474X.89751Michiels J.J., Gadisseur A., Budde U., Berneman Z., Planken M., Schroyens W., Velde A., Vliet H. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Semin Thromb Hemost. 2005; 31 (5): 577–601. DOI: 10.1055/s-2005-922230Michiels J.J., Gadisseur A., Budde U., Berneman Z., Planken M., Schroyens W., Velde A., Vliet H. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Semin Thromb Hemost. 2005; 31 (5): 577–601. DOI: 10.1055/s-2005-922230Collins P., Budde U., Rand H., Federici A. B., Ressler C. M. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia. 2008; 14 (Suppl. 3): 49–55.Collins P., Budde U., Rand H., Federici A. B., Ressler C. M. Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia. 2008; 14 (Suppl. 3): 49–55.Voigtländer M., Langer F. Cancer associated coagulation disorders. Dermatologie (Heidelb). 2022; 73 (10): 809–819. DOI: 10.1007/s00105-022-05056-8Voigtländer M., Langer F. Cancer associated coagulation disorders. Dermatologie (Heidelb). 2022; 73 (10): 809–819. DOI: 10.1007/s00105-022-05056-8Khadadah F., Rupani N, Scott J., Trinkaus M., Teitel J., Sholzberg M. Lymphoma associated acquired von Willebrand syndrome responsive to splenectomy: A case report. E.J. Haem. 2022; 31 (3): 996–999. DOI: 10.1002/jha2.486Khadadah F., Rupani N, Scott J., Trinkaus M., Teitel J., Sholzberg M. Lymphoma associated acquired von Willebrand syndrome responsive to splenectomy: A case report. E.J. Haem. 2022; 31 (3): 996–999. DOI: 10.1002/jha2.486Mondal S., Hollander K.N., Ibekwe S.O., Williams B., Tanaka K. Heyde Syndrome–Pathophysiology and Perioperative Implications. Journal of Cardiothoracic and Vascular Anesthesia. 2021; 35 (11): 3331–9.Mondal S., Hollander K.N., Ibekwe S.O., Williams B., Tanaka K. Heyde Syndrome–Pathophysiology and Perioperative Implications. Journal of Cardiothoracic and Vascular Anesthesia. 2021; 35 (11): 3331–9.Hollestelle M.J, Loots C.M, Squizzato A., Renne T., Bouma B.J, de Groot P.G., et al. Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients. J Thromb Haemost. 2011; 9(5): 953–8. DOI: 10.1111/j.1538-7836.2011.04247.xHollestelle M.J, Loots C.M, Squizzato A., Renne T., Bouma B.J, de Groot P.G., et al. Decreased active von Willebrand factor level owing to shear stress in aortic stenosis patients. J Thromb Haemost. 2011; 9(5): 953–8. DOI: 10.1111/j.1538-7836.2011.04247.xFavaloro E.J., Pasalic A., Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology. 2016; 48(4): 303–18. DOI: 10.1016/j.pathol.2016.03.001Favaloro E.J., Pasalic A., Curnow J. Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology. 2016; 48(4): 303–18. DOI: 10.1016/j.pathol.2016.03.001Novembrino С., Anzoletti M.B., Mancuso M.E., Shinohara S., lPeyvandi F. Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A. Haemophilia. 2018; 2019; 25: 521–526. DOI: 10.1111/hae.13746Novembrino С., Anzoletti M.B., Mancuso M.E., Shinohara S., lPeyvandi F. Evaluation of an automated chromogenic assay for Factor VIII clotting activity measurement in patients affected by haemophilia A. Haemophilia. 2018; 2019; 25: 521–526. DOI: 10.1111/hae.13746Jenkins V., Bowyer A., Burgess C., Gray E., Kitchen S., Murphy P., Platton S., Riddell A., Chowdary P., Lester W. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors’ Organisation guideline. Haemophilia. 2020; 26: 151–155. DOI: 10.1111/hae.13903Jenkins V., Bowyer A., Burgess C., Gray E., Kitchen S., Murphy P., Platton S., Riddell A., Chowdary P., Lester W. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors’ Organisation guideline. Haemophilia. 2020; 26: 151–155. DOI: 10.1111/hae.13903Макарова П.М., Галстян Г.М. Протокол лечения септического шока. В книге: Алгоритмы диагностики и протоколы лечения заболеваний системы крови. В 2 томах. Москва, 2018. С. 1191–1201. ID: 32828517Makarova P.M., Galstyan G.M. Protocol for the treatment of septic shock. In: Diagnostic algorithms and treatment protocols for diseases of the blood system. In 2 v. Moscow, 2018. 1191–1201. (In Russ.). ID: 32828517Pène F., Percheron S., Lemiale V., Viallon V., Claessens Y. E., Marqué S., Charpentier J., Angus D.C., Cariou A., Chiche J. D., Mira J. P. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med. 2008; 36 (3): 690–6. DOI: 10.1097/CCM.0B013E318165314BPène F., Percheron S., Lemiale V., Viallon V., Claessens Y. E., Marqué S., Charpentier J., Angus D.C., Cariou A., Chiche J. D., Mira J. P. Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med. 2008; 36 (3): 690–6. DOI: 10.1097/CCM.0B013E318165314BZuber B., Tran T. C., Aegerter P., Grimaldi D., Charpentier J., Guidet B., Mira J. P, Pène F., CUB Réa Network. Impact of case volume on survival of septic shock in patients with malignancies. Crit Care Med. 2012; 40 (1): 55–62. DOI: 10.1097/CCM.0b013e31822d74baZuber B., Tran T. C., Aegerter P., Grimaldi D., Charpentier J., Guidet B., Mira J. P, Pène F., CUB Réa Network. Impact of case volume on survival of septic shock in patients with malignancies. Crit Care Med. 2012; 40 (1): 55–62. DOI: 10.1097/CCM.0b013e31822d74baAvnery O., Martin M., Bura Riviere A., Barillari, Mazzolai L., Mahé I., Marchena P.J., Verhamme P., Monreal M., Ellis M.H. D dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. J Intern Med. 2020; 287 (1): 32–41. DOI: 10.1111/joim.12969Avnery O., Martin M., Bura Riviere A., Barillari, Mazzolai L., Mahé I., Marchena P.J., Verhamme P., Monreal M., Ellis M.H. D dimer levels and risk of recurrence following provoked venous thromboembolism: findings from the RIETE registry. J Intern Med. 2020; 287 (1): 32–41. DOI: 10.1111/joim.12969Bjøri E., Johnsen H.S., Hansen J B., Braekkan S.K. D dimer at venous thrombosis diagnosis is associated with risk of recurrence. J Thromb Haemost. 2017; 15 (5):917–924. DOI: 10.1111/jth.13648Bjøri E., Johnsen H.S., Hansen J B., Braekkan S.K. D dimer at venous thrombosis diagnosis is associated with risk of recurrence. J Thromb Haemost. 2017; 15 (5):917–924. DOI: 10.1111/jth.13648Lippi G., Franchini M., Targher G., Favaloro E.G. Help me, Doctor! My D dimer is raised. Ann Med. 2008; 40 (8): 594–605. doi: 10.1080/07853890802161015.Lippi G., Franchini M., Targher G., Favaloro E.G. Help me, Doctor! My D dimer is raised. Ann Med. 2008; 40 (8): 594–605. doi: 10.1080/07853890802161015.Gao Y., Li T., Han M., Xiuyong Li, Wu D., Xu Y., Zhu Y., Yan Liu, Wang X., Wang L. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID 19. J Med Virol. 2020; 92 (7): 791 7966. doi: 10.1002/jmv.25770Gao Y., Li T., Han M., Xiuyong Li, Wu D., Xu Y., Zhu Y., Yan Liu, Wang X., Wang L. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID 19. J Med Virol. 2020; 92 (7): 791 7966. doi: 10.1002/jmv.25770Яковлева Е.В., Димитриева О.С., Зозуля Н.И. Коронавирусная инфекция у больных с наследственными коагулопатиями. В сборнике: Российский форум по тромбозу и гемостазу совместно с 10й (юбилейной) конференцией по клинической гемостазиологии и гемореологии. Сборник материалов. Национальная ассоциация по тромбозу и гемостазу. 2020; С. 131.Yakovleva E.V., Dimitrieva O.S., Zozulya N.I. Coronavirus infection in patients with hereditary coagulopathies. In the collection: The Russian Forum on Thrombosis and Hemostasis together with the 10th (anniversary) Conference on Clinical Hemostasiology and Hemorheology. Collection of materials. National Association for Thrombosis and Hemostasis. 2020; 131. (In Russ.).Галстян Г.М. Коагулопатия при Covid 19. Пульмонология. 2020; 30 (5): 645–7. DOI: 10.1 8093/0869-0189-2020-30-5-645-657Galstyan G.M. Coagulopathy in Covid 19. Pulmonology. 2020; 30 (5): 645–657. (In Russ.). DOI: 10.18093/0869-0189-2020-30-5-645-657Binder B.R., Christ G., Gruber F., Grubic N., Hufnagl P., Krebs M., Mihaly J., Prager G.W. “Plasminogen activator inhibitor 1: physiological and pathophysiological roles”. News in Physiological Sciences. 2002; 17: 56–61. PMID11909993.Binder B.R., Christ G., Gruber F., Grubic N., Hufnagl P., Krebs M., Mihaly J., Prager G.W. “Plasminogen activator inhibitor 1: physiological and pathophysiological roles”. News in Physiological Sciences. 2002; 17: 56–61. PMID11909993.Vaughan D.E. PAI 1 and atherothrombosis. Journal of Thrombosis and Haemostasis, 2005; 3: 1879–83. DOI: 10.1111/j.1538-7836.2005.01420.xVaughan D.E. PAI 1 and atherothrombosis. Journal of Thrombosis and Haemostasis, 2005; 3: 1879–83. DOI: 10.1111/j.1538-7836.2005.01420.xMutch N.J., Thomas L., Moore N.R., Lisiak K.M., Booth N.A. TAFIa, PAI 1 and α2 antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. Journal of Thrombosis and Haemostasis, 2007; 5: 812–7. DOI: 10.1111/j.1538-7836.2007.02430.xMutch N.J., Thomas L., Moore N.R., Lisiak K.M., Booth N.A. TAFIa, PAI 1 and α2 antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. Journal of Thrombosis and Haemostasis, 2007; 5: 812–7. DOI: 10.1111/j.1538-7836.2007.02430.xCesaro S., Mauro M, Sattin G, Sartori M.T, Saggiorato G, Paratella A., Tridello G., Bisogno G. PAI 1 and protein C as early markers of veno occlusive disease in patients treated for Wilms tumor. Pediatr Blood Cancer. 2019; 66 (7): e27695. DOI: 10.1002/pbc.27695Cesaro S., Mauro M, Sattin G, Sartori M.T, Saggiorato G, Paratella A., Tridello G., Bisogno G. PAI 1 and protein C as early markers of veno occlusive disease in patients treated for Wilms tumor. Pediatr Blood Cancer. 2019; 66 (7): e27695. DOI: 10.1002/pbc.27695Argren A., Wiman B., Stiller V., Lindmarker P., Sten Linder M., Carlsson A., Holmstrom, Odeberg M.J., Schulman S. Evaluation of low PAI 1 activity as a risk factor for hemorrhagic diathesis. Journal of Thrombosis and Haemoctasis. 2005; 4: 201–8. DOI: 10.1111/j.1538-7836.2005.01709.xArgren A., Wiman B., Stiller V., Lindmarker P., Sten Linder M., Carlsson A., Holmstrom, Odeberg M.J., Schulman S. Evaluation of low PAI 1 activity as a risk factor for hemorrhagic diathesis. Journal of Thrombosis and Haemoctasis. 2005; 4: 201–8. DOI: 10.1111/j.1538-7836.2005.01709.xKahl B.S., Schwartz B.S., Mosher D.F. Profound imbalance of pro fibrinolytic and anti fibrinolytic factors (tissue plasminogen activator and plasminogen activator inhibitor type 1) and severe bleeding diathesis in a patient with cirrhosis: correction by liver transplantation. Blood Coagul Fibrinolysis. 2003; 14: 741–4. DOI: 10.1097/00001721-200312000-00008Kahl B.S., Schwartz B.S., Mosher D.F. Profound imbalance of pro fibrinolytic and anti fibrinolytic factors (tissue plasminogen activator and plasminogen activator inhibitor type 1) and severe bleeding diathesis in a patient with cirrhosis: correction by liver transplantation. Blood Coagul Fibrinolysis. 2003; 14: 741–4. DOI: 10.1097/00001721-200312000-00008ГОСТ Р 53022 3 2008. Технологии лабораторные и клинические. Требования к качеству лабораторных исследований. Правила оценки клинической эффективности лабораторных тестов.– М., 2008.GOST R53022 3 2008. Laboratory and clinical technologies. Requirements for the quality of laboratory tests. Rules for evaluating the clinical effectiveness of laboratory tests.– М., 2008. (In Russ.).Clinical and Laboratory Standards Institute (CLSI). Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory, Approved Guideline. 3rd ed. CLSI document. 2008: 28–33.Clinical and Laboratory Standards Institute (CLSI). Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory, Approved Guideline. 3rd ed. CLSI document. 2008: 28–33.Block B.J., Dolan C.T., Miller G.C., Fitter W.F., Harstell B.D., Crowson A.N., Sheehan W.W., Williams J.D. The data warehouse as a foundation for population based reference intervals. Am.J. Clin. Pathol. 2003; 120: 662–670. DOI: 10.1309/W8J8-5AG4-WDG6-JGJ9Block B.J., Dolan C.T., Miller G.C., Fitter W.F., Harstell B.D., Crowson A.N., Sheehan W.W., Williams J.D. The data warehouse as a foundation for population based reference intervals. Am.J. Clin. Pathol. 2003; 120: 662–670. DOI: 10.1309/W8J8-5AG4-WDG6-JGJ9Jones G.R.D, Berker A., Tate J., Lim C.F., Robertson K. The case for common reference intervals. Clin. Biochem. Rev. 2004; 25: 99–104. PMCID: PMC1904413Jones G.R.D, Berker A., Tate J., Lim C.F., Robertson K. The case for common reference intervals. Clin. Biochem. Rev. 2004; 25: 99–104. PMCID: PMC1904413Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd еd. Wayne, PA: Clinical and Laboratory Standards Institute, 2008; 28(3). Document C28 A3.Defining, Establishing and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd еd. Wayne, PA: Clinical and Laboratory Standards Institute, 2008; 28(3). Document C28 A3.Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Official J. Eur. Commun. 1998; L331: 1–37.Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Official J. Eur. Commun. 1998; L331: 1–37.Qari M.H. High throughput coagulation analyzers review. Comb Chem High hroughput Screen. 2005; 8 (4): 353–60. DOI: 10.2174/1386207054020796Qari M.H. High throughput coagulation analyzers review. Comb Chem High hroughput Screen. 2005; 8 (4): 353–60. DOI: 10.2174/1386207054020796Malati T. Whether western normative laboratory values used for clinical diagnosis are applicable to Indian population? An overview on reference interval. Indian J Clin Biochem. 2009; 24(2): 111–22. DOI: 10.1007/s12291-009-0022-1Malati T. Whether western normative laboratory values used for clinical diagnosis are applicable to Indian population? An overview on reference interval. Indian J Clin Biochem. 2009; 24(2): 111–22. DOI: 10.1007/s12291-009-0022-1Horn P.S, Feng L., Li Y., Pesce A.J. Effect of outliers and nonhealthy individuals on reference interval estimation. Clinical Chemistry. 2001; 47: 2137–45. PMID: 11719478Horn P.S, Feng L., Li Y., Pesce A.J. Effect of outliers and nonhealthy individuals on reference interval estimation. Clinical Chemistry. 2001; 47: 2137–45. PMID: 11719478Bronić A, Margetić S, Coen D., Milić M., Kreši B, Biljak V.R., Krleža J.L. Reporting of activated partial thromboplastin time (aPTT): Could we achieve better comparability of the results? Biochem. Med. 2021; 31(2): 020708. DOI: 10.11613/BM.2021.020708Bronić A, Margetić S, Coen D., Milić M., Kreši B, Biljak V.R., Krleža J.L. Reporting of activated partial thromboplastin time (aPTT): Could we achieve better comparability of the results? Biochem. Med. 2021; 31(2): 020708. DOI: 10.11613/BM.2021.020708Martin Toutain I, Jobic L, Mancic T., Ankri A. Evaluation of the automated coagulation analyzer Sysmex(®) CS 2100i (Siemens). Ann Biol Clin. 2011; 69(6): 699–704. DOI: 10.1684/abc.2011.0624Martin Toutain I, Jobic L, Mancic T., Ankri A. Evaluation of the automated coagulation analyzer Sysmex(®) CS 2100i (Siemens). Ann Biol Clin. 2011; 69(6): 699–704. DOI: 10.1684/abc.2011.0624Martin Toutain I., Jobic L., Mancic T., Brissard A., Ankri A. Evaluation of the automated coagulation analyser Sysmex(®) CS 5100 (Siemens). Ann Biol Clin. 2015; 73(4): 413–9. DOI: 10.1684/abc.2015.1054Martin Toutain I., Jobic L., Mancic T., Brissard A., Ankri A. Evaluation of the automated coagulation analyser Sysmex(®) CS 5100 (Siemens). Ann Biol Clin. 2015; 73(4): 413–9. DOI: 10.1684/abc.2015.1054Appel I.M., Grimminck B., Geerts J., Stigter R., Cnossen M.H., Beishuizen A. Age dependency of coagulation parameters during childhood and puberty. J Thromb Haemost. 2012;10(11): 2254–63. DOI: 10.1111/j.1538-7836.2012.04905.xAppel I.M., Grimminck B., Geerts J., Stigter R., Cnossen M.H., Beishuizen A. Age dependency of coagulation parameters during childhood and puberty. J Thromb Haemost. 2012;10(11): 2254–63. DOI: 10.1111/j.1538-7836.2012.04905.xLethagen S., Hillarp A., Ekholm C., Mattson E., Halldén C., Friberg B. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes. Thromb Haemost. 2008; 99 (6): 1013–8. DOI: 10.1160/TH07-06-0419Lethagen S., Hillarp A., Ekholm C., Mattson E., Halldén C., Friberg B. Distribution of von Willebrand factor levels in young women with and without bleeding symptoms: influence of ABO blood group and promoter haplotypes. Thromb Haemost. 2008; 99 (6): 1013–8. DOI: 10.1160/TH07-06-0419Favaloro E.J., Soltani S., McDonald J., Grezchnik E., Easton L, Favaloro J.W.C. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol. 2006; 125 (5): 796. PMID: 16416741Favaloro E.J., Soltani S., McDonald J., Grezchnik E., Easton L, Favaloro J.W.C. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol. 2006; 125 (5): 796. PMID: 16416741James P. D., Connell N. T., Ameer B, Paola J.D., Eikenboom J., Giraud N., Haberichter S., Jacobs Pratt V., Konkle B., McLintock C., McRae S., Montgomery R.R., O’Donnell J.S., Scappe N., Sidonio R., Flood V.H., Husainat N., Mohamad A.K., Mustafa R.A. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021; 5(1): 280–300 DOI: 10.1182/bloodadvances.2020003265James P. D., Connell N. T., Ameer B, Paola J.D., Eikenboom J., Giraud N., Haberichter S., Jacobs Pratt V., Konkle B., McLintock C., McRae S., Montgomery R.R., O’Donnell J.S., Scappe N., Sidonio R., Flood V.H., Husainat N., Mohamad A.K., Mustafa R.A. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021; 5(1): 280–300 DOI: 10.1182/bloodadvances.2020003265Kitchen S., Jennings I., Woods T. A., Kitchen D. P., Walker I. D., Preston F. E. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemos.t 2006; 32: 492–8. DOI: 10.1055/s-2006-947863Kitchen S., Jennings I., Woods T. A., Kitchen D. P., Walker I. D., Preston F. E. Laboratory tests for measurement of von Willebrand factor show poor agreement among different centers: results from the United Kingdom National External Quality Assessment Scheme for Blood Coagulation. Semin Thromb Hemos.t 2006; 32: 492–8. DOI: 10.1055/s-2006-947863Chandler W.L., Peerschke E.I., Castellone D.D., Meijer P. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Path. 2011; 135: 862–9. DOI: 10.1309/AJCPH5JK4ONENPAEChandler W.L., Peerschke E.I., Castellone D.D., Meijer P. Von Willebrand factor assay proficiency testing. The North American Specialized Coagulation Laboratory Association experience. Am J Clin Path. 2011; 135: 862–9. DOI: 10.1309/AJCPH5JK4ONENPAEHayes T E, Brandt J.T., Chandler W.L., Eby C.S., Kottke Marchant K., Krishnan J., Lefkowitz J.B., Olson J.D., Rund C.R., Van Cott E.M., Cunningham M.T. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program. Semin Thromb Hemost 2006; 32: 499–504. DOI: 10.1055/s-2006-947864Hayes T E, Brandt J.T., Chandler W.L., Eby C.S., Kottke Marchant K., Krishnan J., Lefkowitz J.B., Olson J.D., Rund C.R., Van Cott E.M., Cunningham M.T. External peer review quality assurance testing in von Willebrand disease: the recent experience of the United States College of American Pathologists proficiency testing program. Semin Thromb Hemost 2006; 32: 499–504. DOI: 10.1055/s-2006-947864Sadler J.E., Budde U., Eikenboom J.C., Favaloro E.J., Hill F.G., Holmberg L., et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4: 2103–14. DOI: 10.1111/j.1538-7836.2006.02146.xSadler J.E., Budde U., Eikenboom J.C., Favaloro E.J., Hill F.G., Holmberg L., et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost. 2006; 4: 2103–14. DOI: 10.1111/j.1538-7836.2006.02146.xGadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ. Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol. 2009; 121: 71–84. DOI: 10.1159/000214846Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ. Laboratory diagnosis and molecular classification of von Willebrand disease. Acta Haematol. 2009; 121: 71–84. DOI: 10.1159/000214846Flood V.H., Gill J.C., Morateck P.A., Christopherson P.A., Friedman K.D., Haberichter S.L., et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010; 116: 280–6. DOI: 10.1182/blood-2009-10-249102Flood V.H., Gill J.C., Morateck P.A., Christopherson P.A., Friedman K.D., Haberichter S.L., et al. Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood. 2010; 116: 280–6. DOI: 10.1182/blood-2009-10-249102Lawrie A.S., Stufano F., Canciani M.T., Mackie I.J., Machin S.J., Peyvandi F.A. comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia. 2013; 19: 338–42. DOI: 10.1111/hae.12064Lawrie A.S., Stufano F., Canciani M.T., Mackie I.J., Machin S.J., Peyvandi F.A. comparative evaluation of a new automated assay for von Willebrand factor activity. Haemophilia. 2013; 19: 338–42. DOI: 10.1111/hae.12064Горгидзе Л.А., Мамлеева С.Ю., Пименов М.С. Смирнова А. В., Булгаков А. В., Галстян Г.М. Референсные интервалы для активированного частичного тромбопластинового времени, протромбина по Квику, МНО, тромбинового времени, фибриногена, антитромбина и II, V, VII, VIII, IX, X, XI и XII факторов свертывания, определяемых на автоматическом анализаторе гемостаза Sysmex CS2000i. Медицинский алфавит. 2023; (4): 13–17. DOI: 10.33667/2078-5631-2023-4-13-17Gorgidze L. A., Mamleeva S. Yu., Pimenov M. S., Smirnova A. V., Bulgakov A. V., Galstyan G.M. Reference values of activated partial thromboplastin time, quicks value, INR, thrombin time, fibrinogen, antithrombin and II, V, VII, VIII, IX, X, XI and XII coagulation factors determined with automated Sysmex CS 2000i analyzer. The Medical Alphabet. 2023; (4): 13–17. (In Russ.). DOI: 10.33667/2078-5631-2023-4-13-17Peyvandi F., Oldemburg J., Friedman KD. A critical appraisal of one stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016; 14: 248–2617. DOI: 10.1111/jth.13215Peyvandi F., Oldemburg J., Friedman KD. A critical appraisal of one stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016; 14: 248–2617. DOI: 10.1111/jth.13215Potgieter J.J., Damgaard M., Hillarp A. One stage vs. chromogenic assays in haemophilia A. Eur J Haematol. 2015; 94: 38–44. DOI: 10.1111/ejh.12500Potgieter J.J., Damgaard M., Hillarp A. One stage vs. chromogenic assays in haemophilia A. Eur J Haematol. 2015; 94: 38–44. DOI: 10.1111/ejh.12500Giardina EG, Chen HJ, Sciacca RR, Rabbani LE. Dynamic Variability of Haemostatic and Fibrinolytic Factors in Young Women. J Clin Endocrinol Metab 2004; 89:6 (179–84). DOI: 10.1210/jc.2004-0598Giardina EG, Chen HJ, Sciacca RR, Rabbani LE. Dynamic Variability of Haemostatic and Fibrinolytic Factors in Young Women. J Clin Endocrinol Metab 2004; 89:6 (179–84). DOI: 10.1210/jc.2004-0598Yildiz S.Y., P. Kuru P., Oner E.T., Agirbasil M. Functional Stability of Plasminogen Activator Inhibitor 1. The Scientific World Journal. 2014; 11 pages. DOI: 10.1155/2014/858293Yildiz S.Y., P. Kuru P., Oner E.T., Agirbasil M. Functional Stability of Plasminogen Activator Inhibitor 1. The Scientific World Journal. 2014; 11 pages. DOI: 10.1155/2014/858293Mehta R., Shapiro A.D. Plasminogen activator inhibitor type 1 deficiency. Review Haemophilia. 2008;14 (6): 1255–60. DOI: 10.1111/j.1365-2516.2008.01834.xMehta R., Shapiro A.D. Plasminogen activator inhibitor type 1 deficiency. Review Haemophilia. 2008;14 (6): 1255–60. DOI: 10.1111/j.1365-2516.2008.01834.x

The authors declare that there are no conflicts of interest present.